Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

181.53USD
22 Mar 2019
Change (% chg)

$-1.03 (-0.56%)
Prev Close
$182.56
Open
$182.07
Day's High
$183.85
Day's Low
$181.06
Volume
623,208
Avg. Vol
580,373
52-wk High
$195.81
52-wk Low
$144.15

Latest Key Developments (Source: Significant Developments)

X-Chem And Vertex Expand Existing Partnership
Friday, 4 Jan 2019 08:58am EST 

Jan 4 (Reuters) - Vertex Pharmaceuticals Inc ::X-CHEM AND VERTEX EXPAND EXISTING PARTNERSHIP.X-CHEM - X-CHEM WILL RECEIVE AN UPFRONT PAYMENT.X-CHEM - VERTEX WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PROGRAMS.X-CHEM - X-CHEM STANDS TO RECEIVE ADDITIONAL PAYMENTS LINKED TO THE ACHIEVEMENT OF RESEARCH AND DEVELOPMENT AND REGULATORY MILESTONES.X-CHEM - EXPANDED PARTNERSHIP NOW COMPRISES 14 TARGETS, INCREASING SCOPE OF ORIGINAL AGREEMENT TWO-FOLD.X-CHEM - X-CHEM IS ALSO ELIGIBLE FOR ROYALTIES ON REVENUES FROM MEDICINES ORIGINATING FROM THE COLLABORATION.  Full Article

CRISPR Therapeutics, Vertex Announce FDA "Fast Track" Status For CTX001
Friday, 4 Jan 2019 07:00am EST 

Jan 4 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS AG - COMPANIES ARE ALSO EVALUATING CTX001 FOR TREATMENT OF Β-THALASSEMIA.CRISPR THERAPEUTICS AG - ENROLLMENT IN A PHASE 1/2 TRIAL IN Β-THALASSEMIA IS CURRENTLY OPEN AT MULTIPLE CLINICAL TRIAL SITES IN EUROPE.  Full Article

Vertex Pharmaceuticals And Arbor Biotechnologies Establish Collaboration
Thursday, 3 Jan 2019 08:00am EST 

Jan 3 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND ARBOR BIOTECHNOLOGIES ESTABLISH COLLABORATION TO DISCOVER NOVEL PROTEINS TO ADVANCE DISCOVERY OF GENE-EDITING THERAPIES.VERTEX PHARMACEUTICALS INC - MULTI-YEAR RESEARCH COLLABORATION FUNDED BY VERTEX.VERTEX PHARMACEUTICALS INC - ARBOR TO RECEIVE UP-FRONT CASH PAYMENT AND CONVERTIBLE NOTE INVESTMENT, RESEARCH FUNDING.VERTEX PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL MILESTONES AND ROYALTY PAYMENTS TO ARBOR.VERTEX PHARMACEUTICALS INC - VERTEX WILL OBTAIN AN OBSERVER SEAT ON ARBOR BOARD OF DIRECTORS..  Full Article

Vertex Receives European CHMP Positive Opinion For Cystic Fibrosis drug
Friday, 16 Nov 2018 07:57am EST 

Nov 16 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX RECEIVES EUROPEAN CHMP POSITIVE OPINION FOR ORKAMBI® (LUMACAFTOR/IVACAFTOR) FOR TREATMENT OF CHILDREN WITH CYSTIC FIBROSIS AGED 2 TO 5 YEARS OLD WITH MOST COMMON FORM OF THE DISEASE.VERTEX PHARMACEUTICALS - SUBMISSION WAS SUPPORTED BY DATA FROM PHASE 3 OPEN-LABEL SAFETY STUDY SHOWED TREATMENT WITH WAS WELL TOLERATED.  Full Article

Crispr Therapeutics Says FDA Lifted Clinical Hold On Sickle Cell Disease Drug
Wednesday, 10 Oct 2018 06:28pm EDT 

Oct 10 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS, VERTEX SAYS FDA LIFTED CLINICAL HOLD ON IND APPLICATION FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS - COMPANIES REMAIN ON TRACK TO INITIATE A PHASE 1/2 CLINICAL STUDY IN SCD BY END OF 2018.  Full Article

Health Canada Approves Prsymdeko To Treat Underlying Cause Of Cystic Fibrosis
Thursday, 28 Jun 2018 11:19am EDT 

June 28 (Reuters) - Vertex Pharmaceuticals Inc ::HEALTH CANADA APPROVES PRSYMDEKO™ (TEZACAFTOR/IVACAFTOR AND IVACAFTOR) TO TREAT THE UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER WITH CERTAIN MUTATIONS IN THE CFTR GENE.VERTEX PHARMACEUTICALS - EXPECTS APPROVAL FOR PRSYMDEKO (TEZACAFTOR/IVACAFTOR AND IVACAFTOR) IN EU IN H2 2018.  Full Article

Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81
Thursday, 26 Apr 2018 04:05pm EDT 

April 26 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS.QTRLY EARNINGS PER SHARE $0.81.QTRLY ADJUSTED EARNINGS PER SHARE $0.76.QTRLY TOTAL REVENUES $640.8 MILLION VERSUS $714.7 MILLION.COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION.Q1 EARNINGS PER SHARE VIEW $0.63, REVENUE VIEW $622.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor
Thursday, 26 Apr 2018 04:01pm EDT 

April 26 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS - FIRST PHASE 3 STUDY WILL EVALUATE ABOUT 360 PEOPLE WITH CF WHO HAVE 1 COPY OF F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION.VERTEX PHARMACEUTICALS INC - SECOND PHASE 3 STUDY WILL EVALUATE APPROXIMATELY 100 PEOPLE WITH CF WHO HAVE TWO COPIES OF F508DEL MUTATION.VERTEX - ANNOUNCES RESULTS FOR VX-561 WHEN DOSED AS PART OF A TRIPLE COMBO REGIMEN IN PHASE 2 STUDIES OF PEOPLE WITH 1 F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION.VERTEX PHARMACEUTICALS INC - VX-561 WHEN DOESED AS PART OF THE TRIPLE COMBINATION REGIMENS WERE GENERALLY WELL TOLERATED.  Full Article

Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals
Wednesday, 4 Apr 2018 08:00am EDT 

April 4 (Reuters) - Vertex Pharmaceuticals Inc ::CO'S NOVEL OPTOPATCH PLATFORM.PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES.STATE WILL ALSO RECEIVE ROYALTIES ON DRUG SALES.CO, VERTEX PHARMACEUTICALS WILL COLLABORATE FOR AT LEAST TWO YEARS.VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION.  Full Article

Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis
Wednesday, 21 Feb 2018 04:01pm EST 

Feb 21 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION.VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA.  Full Article

Photo

Vertex cystic fibrosis triple combo therapy succeeds in important trials

Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening genetic condition.